Dai Okemoto

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial.

A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial.

Journal: ESMO gastrointestinal oncology

Published: May 28, 2026

Impact of claudin 18.2 expression on the efficacy of trastuzumab deruxtecan in patients with HER2-positive gastric or gastroesophageal junction cancer.

Impact of claudin 18.2 expression on the efficacy of trastuzumab deruxtecan in patients with HER2-positive gastric or gastroesophageal junction cancer.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Exploratory analysis of HER2-positive/CLDN18.2-positive metastatic gastric and gastroesophageal junction cancer toward future therapeutic development.

Exploratory analysis of HER2-positive/CLDN18.2-positive metastatic gastric and gastroesophageal junction cancer toward future therapeutic development.

Journal: ESMO gastrointestinal oncology

Published: March 11, 2026

Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer.

Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Correction: The efficacy of adjuvant chemotherapy after total mesorectal excision without selective lateral lymph node dissection for locally advanced rectal cancer.

Correction: The efficacy of adjuvant chemotherapy after total mesorectal excision without selective lateral lymph node dissection for locally advanced rectal cancer.

Journal: Scientific reports

Published: January 21, 2026

Durable Complete Response and Potential Cure With Systemic Chemotherapy in Metastatic Gastric Cancer: A Case Series of Patients.

Durable Complete Response and Potential Cure With Systemic Chemotherapy in Metastatic Gastric Cancer: A Case Series of Patients.

Journal: JCO oncology practice

Published: December 19, 2025

Impact of Skeletal Muscle-related Parameters on Survival in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine plus Nab-paclitaxel as First-line Chemotherapy.

Impact of Skeletal Muscle-related Parameters on Survival in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine plus Nab-paclitaxel as First-line Chemotherapy.

Journal: Journal of Cancer

Published: October 13, 2025

Bridging paradigms and shaping the future of resectable gastric cancer: a narrative review of the post-MATTERHORN era.

Bridging paradigms and shaping the future of resectable gastric cancer: a narrative review of the post-MATTERHORN era.

Journal: Gastroenterology report

Published: September 07, 2025

Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors.

Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors.

Journal: JCO precision oncology

Published: August 01, 2025

Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer.

Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer.

Journal: ESMO open

Published: July 01, 2025

The efficacy of adjuvant chemotherapy after total mesorectal excision without selective lateral lymph node dissection for locally advanced rectal cancer.

The efficacy of adjuvant chemotherapy after total mesorectal excision without selective lateral lymph node dissection for locally advanced rectal cancer.

Journal: Scientific reports

Published: April 04, 2025

Impact of claudin 18.2 expression on treatment outcomes of first-line immunochemotherapy in patients with HER2-negative, proficient MMR, PD-L1 CPS ⩾1 metastatic gastric/gastroesophageal junction cancer.

Impact of claudin 18.2 expression on treatment outcomes of first-line immunochemotherapy in patients with HER2-negative, proficient MMR, PD-L1 CPS ⩾1 metastatic gastric/gastroesophageal junction cancer.

Journal: Therapeutic advances in medical oncology

Published: March 26, 2025

Showing 1-12 of 15

Last Updated: 09/26/2026